A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population

PHASE2CompletedINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

July 13, 2024

Study Completion Date

August 1, 2024

Conditions

ObesityOverweight

Interventions

DRUG

VCT220

A small molecule GLP-1R agonist tablet, orally administration, once daily

DRUG

Placebo

Placebo tablet

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Vincentage Pharma Co., Ltd

INDUSTRY

NCT06569355 - A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population | Biotech Hunter | Biotech Hunter